Betrixaban

Betrixaban (PRT054021) is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor with an IC50 of 1.5 nM. Betrixaban shows antithrombotic effect[1][3].

Product Specifications

CAS Number

[330942-05-7]

Product Name Alternative

PRT054021

UNSPSC

12352005

Hazard Statement

H302, H373

Target

Factor Xa

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Betrixaban.html

Purity

98.02

Solubility

DMSO : 25 mg/mL (ultrasonic)

Smiles

N=C(N(C)C)C(C=C1)=CC=C1C(NC2=CC=C(OC)C=C2C(NC(C=C3)=NC=C3Cl)=O)=O

Molecular Formula

C23H22ClN5O3

Molecular Weight

451.91

Precautions

H302, H373

References & Citations

[1]Zhang P, et al. Discovery of Betrixaban (PRT054021), N- (5-chloropyridin-2-yl) -2- (4- (N, N-dimethylcarbamimidoyl) benzamido) -5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor. Bioorg Med Chem Lett. 2009 Apr 15;19 (8) :21|[2]Lu G, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med. 2013 Apr;19 (4) :446-51.|[3]Chan NC, et al. Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism. Vasc Health Risk Manag. 2015 Jun 26;11:343-51.